J. Buolamwini

发表

An Information-Intensive Approach to the Molecular Pharmacology of Cancer

G. S. Johnson, T. Myers, J. Weinstein, 1997, Science.

Identification of N10-Substituted Phenoxazines as Potent and Specific Inhibitors of Akt Signaling*

J. Buolamwini, P. Houghton, J. Easton, 2005, Journal of Biological Chemistry.

CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.

J. Buolamwini, H. Assefa, 2002, Journal of medicinal chemistry.

Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy

J. Buolamwini, Xin Li, Ruiwen Zhang, 2018, Front. Pharmacol..

Novel anticancer agents : strategies for discovery and clinical testing

J. Buolamwini, A. Adjei, 2006 .

Rational Design and Development of Targeted Brain Tumor Therapeutics

D. Bigner, J. Buolamwini, H. Friedman, 2005 .

A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker

J. Buolamwini, Chunmei Wang, 2019, Experimental Hematology & Oncology.

CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1).

J. Buolamwini, A. Gupte, 2009, Bioorganic & medicinal chemistry letters.

Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors.

J. Buolamwini, T. Sanchez, N. Neamati, 2013, Bioorganic & medicinal chemistry letters.

Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS

M. Grever, T. Myers, J. Weinstein, 1994, Stem cells.

Solution NMR Conformational Analysis of the Potent Equilibrative Sensitive (ES) Nucleoside Transporter Inhibitor, S 6-(4-Nitrobenzyl)mercaptopurine Riboside (NBMPR)

J. Buolamwini, J. Barchi, 1997 .

Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2).

S. Schreiber, J. Buolamwini, T. Lewis, 2014, Bioorganic & medicinal chemistry letters.

Targeting EGFR and HER‐2 receptor tyrosine kinases for cancer drug discovery and development

J. Buolamwini, S. Kamath, 2006, Medicinal research reviews.

Ibogaine and a Total Alkaloidal Extract of Voacanga africana Modulate Neuronal Excitability and Synaptic Transmission in the Rat Parabrachial Nucleus In Vitro

S. Kombian, J. Buolamwini, Q. Pittman, 1997, Brain Research Bulletin.

Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action

J. Buolamwini, Ruiwen Zhang, Jianhua Yang, 2020, Cancers.

6-Benzylthioinosine analogues: promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es).

J. Buolamwini, C. K. Chu, V. Yadav, 2005, Biochemical pharmacology.

Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents.

J. Buolamwini, K. Hevener, Richard E. Lee, 2008, Bioorganic & medicinal chemistry.

Molecule–kinase interaction map

J. Buolamwini, S. Kamath, 2005, Nature Biotechnology.

JKA97, a Novel Benzylidene Analog of Harmine, Exerts Anti-Cancer Effects by Inducing G1 Arrest, Apoptosis, and p53-Independent Up-Regulation of p21

J. Buolamwini, Hui Wang, Ruiwen Zhang, 2012, PloS one.

Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S -Transferase Pi Gene Variants EVIDENCE FOR DIFFERENTIAL CATALYTIC ACTIVITY OF THE ENCODED PROTEINS*

J. Buolamwini, F. Ali-Osman, G. Antoun, 1997 .

Cell cycle molecular targets in novel anticancer drug discovery.

J. Buolamwini, 2000, Current pharmaceutical design.

Antisense anticancer oligonucleotide therapeutics.

J. Buolamwini, Hui Wang, H. Wang, 2001, Current cancer drug targets.

Targeting EGFR and HER‐2 receptor tyrosine kinases for cancer drug discovery and development

J. Buolamwini, S. Kamath, 2006, Medicinal research reviews.

Design, synthesis, and evaluation of 2-diethanolamino-4,8-diheptamethyleneimino-2-(N-aminoethyl-N-ethanolamino)-6-(N,N-diethanolamino)pyrimido[5,4-d]pyrimidine-fluorescein conjugate (8MDP-fluor), as a novel equilibrative nucleoside transporter probe.

J. Buolamwini, Wenwei Lin, 2011, Bioconjugate chemistry.

Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4).

J. Buolamwini, Shan Sun, Chunmei Wang, 2013, Biochemical pharmacology.

Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells.

J. Buolamwini, J. Wiley, W. Sawyer, 1993, Cytometry.

Novel Anticancer Agents

J. Buolamwini, A. Adjei, 2006 .

Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors.

J. Buolamwini, N. Neamati, R. Schinazi, 2007, Bioorganic & medicinal chemistry.

Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.

J. Buolamwini, S. Kamath, 2003, Journal of medicinal chemistry.

Novel anticancer drug discovery.

J. Buolamwini, 1999, Current opinion in chemical biology.

Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors.

Nouri Neamati, Haregewein Assefa, Shantaram Kamath, 2004, Journal of medicinal chemistry.

Recent Uses of Palladium Chemistry in Indole Synthesis

J. Buolamwini, S. Patil, 2006 .

Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.

J. Buolamwini, S. Kamath, Shivaputra A Patil, 2005, Current cancer drug targets.

Nucleoside Transport Inhibitors: Structure-Activity Relationships and Potential Therapeutic Applications

J. Buolamwini, 1997, Current Medicinal Chemistry.

Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents

J. Buolamwini, D. Suttle, Ruiwen Zhang, 2017, Drug designing : open access.

Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.

J. Buolamwini, A. Gupte, 2009, Bioorganic & medicinal chemistry letters.

Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.

J. Buolamwini, Zhengxiang Zhu, 2008, Bioorganic & medicinal chemistry.

Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors.

J. Buolamwini, A. Gupte, 2007, Bioorganic & medicinal chemistry.

Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors.

J. Buolamwini, A. Gupte, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter.

J. Buolamwini, J. Furr, Zhengxiang Zhu, 2003, Journal of medicinal chemistry.

Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study.

J N Weinstein, K W Kohn, J. Weinstein, 1995, Journal of medicinal chemistry.

Design, synthesis, and evaluation of 5'-S-aminoethyl-N(6)- azidobenzyl-5'-thioadenosine biotin conjugate: a bifunctional photoaffinity probe for the es nucleoside transporter.

J. Buolamwini, J. Addo, 2004, Bioconjugate chemistry.

Inhibition of gastric tumor growth by a novel Hsp90 inhibitor.

J. Buolamwini, Chunhong Yan, Hemantkumar S. Deokar, 2013, Biochemical pharmacology.

Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.

D. Mukhopadhyay, J. Buolamwini, Hui Wang, 2014, Gastroenterology.

Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.

J. Buolamwini, John K Buolamwini, Wenwei Lin, 2007, Journal of medicinal chemistry.

Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors.

J. Buolamwini, N. Neamati, R. Schinazi, 2011, Bioorganic & medicinal chemistry.

Conjugates of Fluorescein and Saenta (5′-S-(2-Aminoethyl)-N 6-(4-nitrobenzyl)-5′-thioadenosine): Flow Cytometry Probes for the ES Nucleoside Transporter Elements of the Plasma Membrane

J. Buolamwini, C. Cass, J. Wiley, 1994 .

Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice.

J. Buolamwini, Ruiwen Zhang, Wei Wang, 2015, Biomedical chromatography : BMC.

Novel Molecular Targets for Cancer Drug Discovery

John K. Buolamwini, J. Buolamwini, 2002 .

SS-4 is a highly selective small molecule inhibitor of STAT3 tyrosine phosphorylation that potently inhibits GBM tumorigenesis in vitro and in vivo.

P. Yue, J. Turkson, J. Buolamwini, 2022, Cancer letters.

A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study.

J. Buolamwini, Ruiwen Zhang, Wei Wang, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

K. Srivenugopal, J. Buolamwini, Hui Wang, 2014, Nature Communications.

Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer

J. Buolamwini, M. Fan, Chunmei Wang, 2013, Cancer Prevention Research.

A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY

J. Buolamwini, 2006 .

Therapeutic Discovery A Small-Molecule Inhibitor of MDMX Activates p 53 and Induces Apoptosis

John K. Buolamwini, J. Buolamwini, Hongbo Wang, 2011 .

A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

John K. Buolamwini, J. Buolamwini, Hongbo Wang, 2010, Molecular Cancer Therapeutics.

Overview of novel anticancer drug targets.

J. Buolamwini, H. Assefa, 2003, Methods in molecular medicine.

Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S-Transferase Pi Gene Variants

J. Buolamwini, F. Ali-Osman, G. Antoun, 1997, The Journal of Biological Chemistry.

A protein expression database for the molecular pharmacology of cancer

J N Weinstein, D A Scudiero, T G Myers, 1997, Electrophoresis.

Tyrosine Phosphorylation of the Human Glutathione S-Transferase P1 by Epidermal Growth Factor Receptor*

D. Bigner, J. Buolamwini, T. Haystead, 2009, The Journal of Biological Chemistry.

Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.

Qianjun Li, H. Wakimoto, R. Martuza, 2010, Cancer research.

An Integrated Computational and Experimental Binding Study Identifies the DNA Binding Domain as the Putative Binding Site of Novel Pyrimidinetrione Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors

P. Yue, J. Turkson, J. Buolamwini, 2017 .

Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity.

J. Buolamwini, Chunmei Wang, Surekha R. Pimple, 2010, Biochemical pharmacology.

Homology Modeling of Human Concentrative Nucleoside Transporters (hCNTs) and Validation by Virtual Screening and Experimental Testing to Identify Novel hCNT1 Inhibitors.

J. Buolamwini, Hemant Kumar Deokar, Hilaire Playa Barch, 2017, Drug designing : open access.

Impact of Resistance Mutations on Inhibitor Binding to HIV-1 Integrase

Qin Xu, Jeremy C. Smith, Qi Chen, 2013, J. Chem. Inf. Model..

Molecular targets in cancer drug discovery: cell-based profiling.

J. Weinstein, J. Buolamwini, 2000, Current pharmaceutical design.

Two novel cycloartane-type triterpene glycosides from the roots of Astragalus prusianus

J. Buolamwini, İ. Çalış, I. Khan, 2001 .

Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action

K. Srivenugopal, J. Buolamwini, Ruiwen Zhang, 2020, Cells.

Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction.

J. Buolamwini, P. Hofmann, Z. Zhu, 2007, American journal of physiology. Heart and circulatory physiology.

Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3.

J. Buolamwini, Hemantkumar S. Deokar, Mrunalini Deokar, 2023, Molecular diversity.

Dynamic Docking Study of the Binding of 1-Chloro-2,4- Dinitrobenzene in the Putative Electrophile Binding Site of Naturally Occurring Human Glutathione

J. Buolamwini, F. Ali-Osman, 1999 .

3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Haregewein Assefa, Shantaram Kamath, John K. Buolamwini, 2003, J. Comput. Aided Mol. Des..

Novel anticancer drug protocols

J. Buolamwini, A. Adjei, 2003 .

Homology Model-Guided 3D-QSAR Studies of HIV-1 Integrase Inhibitors

Xiaolin Cheng, John K. Buolamwini, Horrick Sharma, 2012, J. Chem. Inf. Model..

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

K. Srivenugopal, J. Buolamwini, Hui Wang, 2014, Nature Communications.